The Incidence of Post-Operative Fibrinoid Syndrome in Diabetic Eyes Receiving a Dexamethasone Implant During Pars Plana Vitrectomy Surgery.

Clinical ophthalmology (Auckland, N.Z.) Pub Date : 2025-09-30 eCollection Date: 2025-01-01 DOI:10.2147/OPTH.S536499

Reem ElSheikh, Sairi Zhang, Mohammad Z Siddiqui, Muhammad Z Chauhan, Ahmed B Sallam, Sami H Uwaydat

{"title":"The Incidence of Post-Operative Fibrinoid Syndrome in Diabetic Eyes Receiving a Dexamethasone Implant During Pars Plana Vitrectomy Surgery.","authors":"Reem ElSheikh, Sairi Zhang, Mohammad Z Siddiqui, Muhammad Z Chauhan, Ahmed B Sallam, Sami H Uwaydat","doi":"10.2147/OPTH.S536499","DOIUrl":null,"url":null,"abstract":"Introduction: The dexamethasone implant (DEX) and pars plana vitrectomy (PPV) are both used to treat diabetic retinopathy. A rare complication of vitrectomy is post-operative fibrinoid syndrome (POFS). We report the incidence of POFS when PPV is combined with DEX injection in diabetic eyes.Methods: One hundred and five eyes of patients with diabetic retinopathy undergoing concurrent PPV and DEX were retrospectively analyzed.Results: Mean BCVA improved from 1.06 logMAR to 0.78 (p=0.05) at final follow-up. Mean CST was found to have a statistically insignificant decrease from 360 ± 154 µm to 314 ± 99 µm at final visit (p=0.13). Four eyes (3.8%) developed POFS. No major surgical complications were encountered.Conclusion: Combining PPV with DEX is safe and effective in patients with diabetic retinopathy. Our results showed an improvement in mean BCVA and a decrease in CST. The incidence of POFS was 3.8%, which is not significantly different from previously published data in 1982.","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"3567-3572"},"PeriodicalIF":0.0000,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12495912/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical ophthalmology (Auckland, N.Z.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/OPTH.S536499","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The dexamethasone implant (DEX) and pars plana vitrectomy (PPV) are both used to treat diabetic retinopathy. A rare complication of vitrectomy is post-operative fibrinoid syndrome (POFS). We report the incidence of POFS when PPV is combined with DEX injection in diabetic eyes.

Methods: One hundred and five eyes of patients with diabetic retinopathy undergoing concurrent PPV and DEX were retrospectively analyzed.

Results: Mean BCVA improved from 1.06 logMAR to 0.78 (p=0.05) at final follow-up. Mean CST was found to have a statistically insignificant decrease from 360 ± 154 µm to 314 ± 99 µm at final visit (p=0.13). Four eyes (3.8%) developed POFS. No major surgical complications were encountered.

Conclusion: Combining PPV with DEX is safe and effective in patients with diabetic retinopathy. Our results showed an improvement in mean BCVA and a decrease in CST. The incidence of POFS was 3.8%, which is not significantly different from previously published data in 1982.

查看原文本刊更多论文

玻璃体切除手术中接受地塞米松植入的糖尿病眼术后纤维蛋白样综合征的发生率。

地塞米松植入（DEX）和玻璃体切除（PPV）均用于治疗糖尿病视网膜病变。玻璃体切除术后纤维蛋白样综合征是一种罕见的并发症。我们报道了当PPV联合DEX注射用于糖尿病眼时POFS的发生率。方法：对105例糖尿病视网膜病变同时行PPV和DEX手术的患者进行回顾性分析。结果：最终随访时，平均BCVA由1.06 logMAR改善至0.78 （p=0.05）。平均CST在最后一次访问时从360±154µm下降到314±99µm，差异无统计学意义（p=0.13）。4只眼（3.8%）出现POFS。无重大手术并发症。结论：PPV联合DEX治疗糖尿病视网膜病变安全有效。我们的结果显示平均BCVA改善，CST降低。POFS的发生率为3.8%，与1982年公布的数据没有显著差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical ophthalmology (Auckland, N.Z.)

CiteScore

4.10

自引率

0.00%

发文量